article thumbnail

Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine

Pharmaceutical Technology

The company says that these four serotypes represent roughly 10–15% of bacteria causing pneumococcal disease in adults. Pneumococcal vaccines are used to inoculate individuals against infections caused by the Streptococcus pneumoniae bacteria. This is in addition to its long-available pneumococcal polysaccharide vaccine PPSV23.

article thumbnail

Cyfendus Anthrax Vaccine Wins FDA Approval

XTalks

Anthrax is a rare, yet severe disease caused by the bacterium B. The bacteria usually enter the body through wounds, but infection can also occur through contaminated meat or inhalation of spores. Additionally, 533 participants received at least one dose of the comparator-licensed anthrax vaccine, BioThrax (Anthrax Vaccine Adsorbed).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GSK bolsters vaccines division with $3.3bn swoop on Affinivax

pharmaphorum

Last year, Affinivax reported positive phase 2 results with ASP3772, which targets 24 of the common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

Late in 2022, AbbVie partnered with HotSpot Therapeutics and announced an exclusive worldwide collaboration and option to license agreement for their interferon regulatory factor 5 (IRF5) inhibitor program for autoimmune disease treatment. In 2022, the FDA proceeded to grant official licensing for Moderna’s Spikevax COVID-19 vaccine.

Sales 98